A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer

NCT02488564 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

HER-2 Positive Breast Cancer

Interventions

DRUG: Liposomal doxorubicin
DRUG: Docetaxel
DRUG: Trastuzumab
DRUG: Metformin

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS